Brazil, South Africa, Thailand, Uganda and the US are part of a study to evaluate safety and efficacy of sofosbuvir/velpatasvir with minimal monitoring (MINMON) approach in treatment-naïve persons without decompensated cirrhosis.
MINMON included four components: (1) no pre-treatment genotyping; (2) all tablets dispensed at entry; (3) no on-treatment visits/laboratory monitoring; and (4) two remote contacts at weeks 4 (adherence assessment) and 22 (to schedule outcome assessment at week 24). The primary efficacy outcome was sustained virological response (SVR).
Conclusion: The MINMON approach with sofosbuvir/velpatasvir treatment was safe and achieved SVR comparable to real-world data. Coupled with innovative case finding strategies, this strategy could be crucial to the global HCV elimination agenda. Remain the most important questions of the effective access to sofosbuvir/velpatasvir and at what price.
The study results are published in The Lancet Gastroenterology & Hepatology and can be accessed here.
An accompanying comment can be accessed here.